

DATE: March 15, 2003

SHEET 1 of 3

(Form PTO 1449)

FORM PTO-1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6789.US.03  APPLICANT(S)  M. D. Cowart, et al.		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(37 CFR 1.98 (b))	(Use several sheets if necessary)	FILING DATE September 5, 2003	(not yet assigned)	

#### **U.S.PATENT DOCUMENTS**

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
EB.	Al	5,792,768	08/11/98	Kulagowski et al.	-		
£B	A2	3,472,854	10/14/69	Archer/Sterling			
£B.	A3	5,714,498	02/03/98	Kulagowski et al			
EB	A4	3,362,956	01/09/68	Archer			

### FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	<u> </u>	DOCUMENT NUMBER	PUBLIC- ATION	COUNTRY OR		SUB -	TRA LAT	
	-		DATE	PATENT OFFICE	CLASS	CLASS	YES	NO
EB	ВІ	98/31368	07/23/98	wo				
	B2	02/88093	07/11/02	wo				
	B3	0,0/23056	04/27/00	wo				
	B4	0 882 718	12/09/98	EP	<del>-</del>			
	B5	0 468 884	07/24/91	EP				<b> </b> -
士	B6	2 154 605	09/14/99	ES			X	<u> </u>

# OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

		LANGOTTON MARKET TO THE PROPERTY OF THE PROPER
LB	101	Andersson, K. et al., "Physiology of penile erection," Physiol. Rev. 75:191-236 (195)
	C2	Pandala A M et al. WAnti Julianus Anni I al. 100
		Bendele, A.M. et al., "Anti-Inflammatory Activity of Pergolide, a Dopamine Receptor Agonist," Journal of Pharmacology and Experimental Therapeutics 259(1):169-175 (1991)
1	C3	Chen, F.F. et al., "Effects of dopamine, Apomorphine, -Hydroxybutyric Acid, Haloperidol and Pimozide on
- 1		Reflex Bradycardia in Rats," Journal of Pharmacology and Experimental Therapeutics 214(2):427-432
;		(1000)
	<u>L</u>	(1980)
- 1	C4	DeGroat, W. et al., "Neural Control of Penile Erection, in : Nervous control of urogenital system,"
- I	1	Hardwood Academic Publishers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993)
	1772	That wood Academic I donshers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993)
	C5	Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine
Y		versus placebo in men with erectile dysfunction," Urology 56:130-135 (2000)
EXAMINER		
CAMBILITY		DATE CONSIDERED
	XX	Sembard 9/30/05
EXAMINER-	Initial	illation considered New York About 18 5
not considera	11111111111111111111111111111111111111	citation considered. Draw line through citation if not in conformance and
HUL CONSIDER	n. Incini	THE CORV OF This form with next sommunication to a!'t

**DATE:** March 12, 2003

SHEET 2 of 3

#### Form PTO - 1449 (Modified)

(Modified) (37 CFR 1.98 (b))	PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6789.US.03	serial no. (not yet assigned)	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S) M. D. Cowart, et al.		
	(Use several sheets if necessary)	FILING DATE September 5, 2003	(not yet assigned)	

### **U.S.PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLICA- TION	COUNTRY OR		SUB	TRA LAT	
		DATE	PATENT OFFICE	CLASS	CLASS	YES	NO
1							
<del> </del>							
1		1					

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

FB	C6	Hahn, R.A. et al., "Primate Cardiovascular Responses Mediated by Dopamine Receptors: Effects of N, N-di- n-Propyldopamine and LY171555," Journal of Pharmacology and Experimental therapeutics 229(1):132-138 (1984)
	C7	Harris, M. C. et al., "Sequential N-Arylation of Primary Amines as a Route to Alkyldiarylamines," J. Org. Chem. 64:6019-6022 (1999)
	C8	Hrib, N. J., et al., "The dopamine D <sub>4</sub> receptor: a controversial therapeutic target," Drugs of the Future 2000 25(6):587-611
	C9	Koch, V. et al., "Chemistry of 3-Hydroxypyridien part 2: Synthesis of 5,6-Dihalo-3hydroypyridines," Synthesis 499-501 (1990)
	C10	Lissoni, et al., "Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer- related hyperprolactinemia," Neuroendocrinology Letters ISSN 21:405-408 (2000)
	CH	Lynch, J.K. et al., "Efficient asymmetric synthesis of ABT-594; a potent, orally effective analgesic," Tetrahedron: Asymmetry 9:2791-2794 (1998)
	C12	Melis, M et al., "Dopamine and Sexual Behavior," Neurosience and Biobehavioral Reviews, 19(1):193-35 (1995)
	C13	Milligan, G. et al., "Chimaeric G proteins: their potential use in drug discovery," Trends Pharmacol Sci 20:118-124 (1998)
	C14	Missale, C. et al. "Dopamine receptors: from structure to function," Physiol Rev 78:189-225 (1998)
4	C15	Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," Urologic Clinics of North America, vol. 22:879-886 (1995)
EXAMINER	X A	Beinhaud DATE CONSIDERED 9/30/65
not considered	Initial c	itation considered. Draw line through citation if not in conformance and de copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: March 12, 2003

SHEET \_3\_ of \_3\_

#### Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SERIAL NO. (not yet assigned)		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S) M. D. Cowart, et al.		
(37 CFR 1.98 (b))	(Use several sheets if necessary)	September 5, 2003	(not yet assigned)	

#### **U.S.PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
·						<u> </u>

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLICA- TION	COUNTRYOR		SUB	TRANS- LATION
	DATE	PATENT OFFICE	CLASS	CLASS	YES NO

# OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	****	
_EB	C16	Moreland, RB, et al., "Prospectives for Pharmacotherapy of Male Erectile Dysfunction," Curr Opinion CPNS Invest Drugs, 2:283-302 (2000)
	C17	Primus, R. et al., "Localization and characterization of dopamine D <sub>4</sub> binding sites in rat and human brain by use of the novel D <sub>4</sub> receptor-selective ligand [ <sup>3</sup> H]NGD 94-1," J. Pharmacol Exp. Ther 282:1020-1027 (1997)
	C18	Suzuki, M. et al., "D <sub>3</sub> dopamine receptor mRNA is widely express in human brain," Brian Res 779:58-74 (1998)
	C19	Vallone, D. et al., "Structure and function of dopamine receptors," Neurosci Biobehav. Rev. 24:125-132 (2000)
	C20	Wagaw, S. et al., "The Synthesis of Aminopyridines: A Method Employing Palladium-Catalyzed Carbon-Nitrogen Bond Formation," J. Org. Chem 61:7240-7241 (1996)
	C21	Yang B. et al., "Palladium-catalyzed amination of aryl halides and sulfonates," Journal of Organometallic Chemistry 576:125-146 (1999)
	C22	Bevilacqua et al., "Pharmacology for erectile dusfunction" TIPS 21:484-489(2000)
	C23	Shvedov et al., "Catalytic alkylation of amines with alcohols", Zhurnal Organicheskoi Khimii 6(9): 1883-1840 (1970)
1	C24	Pugsley et al., "The discovery of PD89211 and related compounds: selective dopamine D4 receptor antagonists, "Progress in Neuro-Psychopharmacology & biological Psychiatry 26(2):219-226 (2002)
EXAMINER		Lembard DATE CONSIDERED 9/30/0x
examiner: not considered	Initial of	citation considered. Draw line through citation if not in conformance and de copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: May 10, 2005

SHEET \_1 of \_1\_

FORM PTO-1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6789.US.O3	SERIAL NO. 10/656,672	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S) M. D. Cowart, et al.		
(37 CFR 1.98 (b))	(Use several sheets if necessary)	FILING DATE September 5, 2003	1642	

#### **U.S.PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	<u> </u>	•	*			
			<del></del>			
	-					
					<u></u>	

#### FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS		RANS- ATION	
EB	BI	94/22839	13.10.94	WO	CLASS .	CLASS	123	NO	

### OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

EB	CI	Berge, S.M. et al., J. Pharmaceutical Sciences 66:1et seq (1977)		
EB	C2	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," Urology 161:214 (abstract 821) (1999)		
FB	C3	Sule, D.P. et al., "Synthesis and Anthelmintic activity of 2-(N4-Substituted-N1-Piperazinyl) Methyl 5-(or 6) – substituted benzimidazoles," Bull. Haffkine Inst. 6(2):62-64 (1978)		
EB	C4 .	"IUPAC 1974 Recommendation for Section E, Fundamental Stereochemistry," Pure Appl. Chem. 45:13-30 (1976)		
EVARABIET	<del></del>	A DATE CONCIDENCE		

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)